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Abstract
Background: Lithium is a commonly prescribed drug with a narrow therapeutic index, and recognised adverse
effects on the kidneys and thyroid. Clinical guidelines for the management of bipolar affective disorder published
by The National Institute for Health and Clinical Excellence (NICE) recommend checks of renal and thyroid function
before lithium is prescribed. They further recommend that all patients who are prescribed lithium should have their
renal and thyroid function checked every six months, and their serum lithium checked every three months.
Adherence to these recommendations has not been subject to national UK audit.
Methods: The Prescribing Observatory for Mental Health (POMH-UK) invited all National Health Service Mental
Health Trusts in the UK to participate in a benchmarking audit of lithium monitoring against recommended
standards. Data were collected retrospectively from clinical records and submitted electronically.
Results: 436 clinical teams from 38 Trusts submitted data for 3,373 patients. In patients recently starting lithium,
there was a documented baseline measure of renal or thyroid function in 84% and 82% respectively. For patients
prescribed lithium for a year or more, the NICE standards for monitoring lithium serum levels, and renal and
thyroid function were met in 30%, 55% and 50% of cases respectively.
Conclusions: The quality of lithium monitoring in patients who are in contact with mental health services falls
short of recognised standards and targets. Findings from this audit, along with reports of harm received by the
National Patient Safety Agency, prompted a Patient Safety Alert mandating primary care, mental health and acute
Trusts, and laboratory staff to work together to ensure systems are in place to support recommended lithium
monitoring by December 2010.
Background
Lithium is licensed for the acute treatment of mania,
prophylaxis in bipolar disorder and to augment antide-
pressants in treatment-refractory recurrent depression.
Its use for these indications is supported by contempor-
ary UK treatment guidelines [1-3]. For most patients,
treatment with lithium is long term [4].
Lithium is generally ineffective when the serum level
is below 0.4 mmol/L, and very few patients will benefit
from levels greater than 1.0 mmol/L [5]. Increasing
levels above this upper threshold are associated with
signs and symptoms of lithium toxicity such as confu-
sion, seizures and renal damage. Treatment guidelines
therefore recommend that the serum lithium level
should be checked regularly throughout treatment to
ensure that it remains within the therapeutic range.
With regard to the frequency of monitoring, the NICE
guideline for bipolar disorder [1] recommends that
serum lithium is checked every 3 months while the Brit-
ish Association for Psychopharmacology guidelines for
bipolar disorder [3] recommend every 3-6 months.
The side-effect profile of lithium is well established. As
lithium is almost wholly excreted in the urine, any
changes in renal function or fluid balance caused by
intercurrent illness or drug treatment can potentially lead
to lithium accumulation, which in turn can lead to renal
damage and toxicity. Lithium treatment also increases
the risk of clinical hypothyroidism up to 5-fold, through
complex mechanisms that are unrelated to dose [5].
These potential problems necessitate pre-treatment
checks of renal and thyroid function, followed by regular
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checks for the duration of lithium treatment for all
patients. The NICE guideline for bipolar disorder [3]
recommends that renal and thyroid function tests are
conducted every 6 months while the BAP guideline for
bipolar disorder [1] recommends that this biochemical
monitoring is carried out every 12 months. In addition,
lithium treatment is associated with weight gain [6] and
NICE recommends that patients receiving lithium should
have their body weight, BMI or waist circumference mea-
sured at least annually [3].
In the UK, the Quality and Outcomes Framework
(QOF) also sets targets for the monitoring of patients
receiving lithium in primary care [7]. QOF targets are
less strict than those recommended by NICE. The data
collected for each practice are the proportions of
patients receiving lithium who have had their thyroid
and renal function checked in the previous 15 months
(mental health standard 4) and have had a serum
lithium level within the therapeutic range documented
in the previous 6 months (mental health standard 5).
Despite the existence of explicit standards for monitor-
ing patients who are prescribed lithium, a number of
local audits conducted in different areas of the UK over
the last 20 years have found this monitoring to be sub-
optimal [8-11]. There are no published audits that are
UK-wide or that post-date the publication of the NICE
guideline for the management of bipolar disorder.
In 2009, 38 mental health Trusts in the UK participated
in a baseline audit of the quality of lithium monitoring as
part of a quality improvement program (QIP) run by the
Prescribing Observatory for Mental Health (POMH-UK).
The audit standards were derived from the recommenda-
tions in the NICE guideline for the management of bipolar
disorder [3], and were as follows:
1: The following tests/measures should be undertaken
before initiating treatment with lithium: (a) renal func-
tion tests; urea and electrolytes (U&Es) including creati-
nine (or e-GFR or creatinine clearance); (b) thyroid
function tests (TFTs), and; (c) body weight or BMI or
waist circumference
2: The following tests/measures should be conducted
during maintenance treatment with lithium: (a) serum
lithium level every 3 months; (b) renal and thyroid func-
tion tests every 6 months, and; (c) weight or BMI or
waist circumference during the last year
We report on systems for managing lithium treatment
within these 38 mental health Trusts, and on how
lithium monitoring compared with the standards set by
NICE and the targets set by the QOF.
Methods
The Prescribing Observatory for Mental Health (POMH-
UK) conducts clinical audit-based QIPs that focus on
prescribing practice in mental health. Each QIP starts
with a baseline audit of practice against evidence-based
clinical standards, and this is followed by the delivery of a
benchmarked audit report, the provision of change inter-
ventions and finally a re-audit 12-18 months later.
Further information about POMH can be found at www.
rcpsych.ac.uk/pomh.
The sample
POMH-UK invited all National Health Service (NHS)
Trusts in the United Kingdom providing specialist mental
health services to participate in a QIP focusing on the
quality of monitoring of patients prescribed lithium. This
was done in a number of ways which included; (1) e-mail
communication with the POMH leads in eligible Trusts;
(2) discussion with clinicians and clinical audit staff at
POMH regional workshops, and: (3) letters of invitation to
Trust chief executives, medical directors, chief pharmacists
and clinical governance leads. Thirty-eight Trusts chose to
participate. Very few UK services have a central register of
patients prescribed lithium and Trusts used a variety of
methods to identify their sample. These included a census
of prescriptions, pharmacy records, pathology records and
the caseloads of individual clinical teams. Services could
enter data for as many patients as they wished.
Data collection
For each patient the following data were collected: age,
gender, ethnicity, and primary psychiatric diagnosis.
For the subsample of patients who had started lithium
treatment in the past year, the following data were col-
lected: the presence of documented pre-treatment mea-
sures of renal and thyroid function and body weight (or
BMI or waist circumference), and documented evidence
that the patient had been advised of the side effects of
lithium, the risk factors for lithium toxicity and the
signs and symptoms of toxicity.
For the remaining patients, who had been prescribed
lithium for longer than year, the data collected included
the number of occasions on which a serum lithium level,
renal and thyroid function tests and a measure of
body weight had been measured over the past 12 months.
Multiple tests conducted within the same month were
counted as a single test as these were likely to have been
conducted for a purpose other than routine monitoring.
For each patient, all the data were collected from their
clinical records, and submitted to POMH using a secure
web-based system called SNAP. Data collection fields
relevant to the audit standards were mandatory in that
it was not possible to submit data for cases where the
mandatory fields had not been completed. The identity
of each Trust submitting data was known to POMH,
but the identities of the individual clinical teams and
patients were not. Only the national level data are
reported here.
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Trust Questionnaire
Each Trust was sent a questionnaire relating to systems
for managing patients who were prescribed lithium, both
within the Trust and across the interface with primary
care. With respect to systems within the Trust, the ques-
tionnaire covered whether: (1) there were locally adopted
guidelines for managing patients prescribed lithium; (2)
Trust clinicians had electronic access to pathology
results; (3) care was wholly or partly delivered through
lithium clinics and; (4) whether the Trust had access to
an electronic database containing details of all patients
prescribed lithium, and if so, whether this system gener-
ated automatic reminders that blood tests were due.
Further questions were asked about systems for sharing
care between the mental health Trust and primary care.
Statistical analysis
Each of the four outcomes of interest (measures of
serum lithium level, renal function, thyroid function and
body weight) was treated as a binary measure; whether
or not the standard had been met. Logistic regression
analyses were conducted to explore the contribution of
several possible explanatory variables (age, gender, eth-
nicity, psychiatric diagnosis, and care provider) to these
binary outcomes. The separate effect of each predictor
variable upon each outcome was tested in a series of
univariable analyses. Subsequently, the joint effect of the
variables upon each outcome was examined in multi-
variable analyses, using a backwards selection procedure
to retain only the statistically significant variables. Data
were analysed using SPSS, version 17.
Results
The sample
Four hundred and thirty six clinical teams from 38 mental
health Trusts submitted data for 3,373 patients. 1,972
(59%) patients were female, 2,667 (79%) were white British,
and the mean age of the sample was 55 years (sd 16, range
17-94 years). For 1,919 (57%) patients the primary clinical
diagnosis was bipolar disorder, 857 (25%) unipolar depres-
sion, 370 (11%) a psychotic spectrum disorder (ICD10
F20-29), 161 (5%) another psychiatric diagnosis, and for
66 (2%) no psychiatric diagnosis was documented.
Performance against the standards in the sub-sample
of patients who had been prescribed lithium for
less than 1 year
397 patients had been prescribed lithium for less than
1 year. Of these, 334 (84%) had a documented baseline
test of renal function including creatinine; the respective
figures for thyroid function and body weight were 325
(82%) and 145 (37%).
With respect to documentation regarding the provision
of relevant information to patients, this was present for
the side effects of lithium in 244 (62%) cases, the risk fac-
tors for toxicity in 166 (42%), and the signs and symptoms
of toxicity in 178 (45%) of cases. These proportions did
not differ for the sub-groups of patients who were either
younger than 65 years or older than 65 years.
Performance against the standards in the sub-sample
of patients who had been prescribed lithium for
more than a year
2,976 patients had been prescribed lithium for more
than a year. With respect to lithium serum levels, 68%
of cases had 2 or more documented tests in the previous
year, thus meeting the QOF standard, while 30% had 4
or more tests in the last year, reaching the NICE stan-
dard. With respect to tests of renal function, which
included creatinine, 81% of cases had one or more
documented tests in the last year, thereby meeting the
QOF standard, while 55% had two or more documented
tests and therefore met the NICE standard. The respec-
tive figures for thyroid function were 82% and 50%. For
206 (7%) patients there was no documented evidence
that any of the recommended monitoring tests/measures
had been conducted in the previous year.
Further details of performance against the NICE and
QOF standards are shown in Table 1. The summary
results can be compared with those of previous pub-
lished UK audits in Table 2. Table 3 provides further
information on the demographic and clinical character-
istics of the subsample of patients who been prescribed
lithium for a year or more. It also indicates the relation-
ship between each these variables and the extent to
which the audit standards derived from the NICE gui-
dance were being met.
Factors predicting monitoring performance
The univariable analyses examined the effect of potentially
relevant clinical or demographic factors (age, gender, eth-
nicity, ICD-10 psychiatric diagnosis and type of clinical
service providing care, e.g. general adult psychiatry,
Table 1 Lithium monitoring tests or measures conducted
during maintenance treatment (n = 2,976)
Number of
tests in last
year
U&Es with
creatinine
Thyroid
function
tests
Weight/BMI/
waist
circumference
Serum
lithium
0 553 (19%) 524 (18%) 2155 (72%) 273 (9%)
1 795 (27%) 976 (33%) 416 (14%) 668 (22%)
2 592 (20%) 693 (23%) 155 (5%) 572 (19%)
3 466 (16%) 453 (15%) 90 (3%) 561 (19%)
4 313 (11%) 208 (7%) 62 (2%) 503 (17%)
5 or more 257 (9%) 122 (4%) 98 (3%) 399 (13%)
Bold text Neither NICE standards nor QOF targets met.
Bold and italics Meets QOF targets, but not NICE standards.
Normal text Meets both QOF targets and NICE standards.
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learning disability, forensic service, etc.) on whether the
four outcomes were met. At a significance level of p ≤
0.001, age (being over 65 years) and service type (elderly
mental health services) were associated with monitoring of
serum lithium level and renal function, service type (again
essentially elderly mental health services) was associated
with monitoring of thyroid function, while diagnosis (schi-
zophrenia spectrum disorder) and service type (forensic
and learning disability services) were associated with mea-
surement of body weight.
The multivariable analyses addressed biochemical
monitoring, and revealed that only service type (elderly
mental health services) was associated with meeting the
standards for monitoring serum lithium (OR 1.34; 95%
CI 1.13-1.58) and renal function (OR 1.45; 1.12-1.87),
both at a significance of p ≤ 0.001.
Trust questionnaire
All 38 Trusts returned a completed questionnaire.
Twenty-eight (74%) Trusts reported having fully adopted
formal guidelines; most using the monitoring standards
recommended in the NICE bipolar guidelines (n = 20) or
British National Formulary (n = 11). Twenty-four (63%)
Trusts reported having at least one lithium clinic, but
only 8 (21%) had Trust-wide electronic access to results
and 1 (3%) a local electronic database specifically for
lithium that automatically produced prompts when tests
were due. Fourteen (37%) Trusts had formally agreed,
shared-care guidelines for patients managed concurrently
with primary care, and 5 (13%) had electronic systems
shared Trust-wide between primary and secondary care.
Discussion
The main findings were that documented evidence that
baseline tests of renal and thyroid function had been con-
ducted was found for just over four-fifths of patients
recently commenced on lithium therapy, and for those
patients receiving lithium treatment for a year or more,
the frequency of monitoring of serum lithium and renal
and thyroid function met the standards set by NICE in
less than a third to just over a half of patients, depending
on the measure.
Previous published audits of the quality of lithium
monitoring have tended to be relatively small and locality
specific. They also pre-date the NICE bipolar guideline,
and used older audit standards from the British National
Formulary (see table 2). These factors render it difficult
to directly compare our findings with those of the audits
conducted earlier in this area, but there is little to suggest
a trend for improvement over time.
Why is recommended monitoring not carried out?
Possible explanations for suboptimal monitoring may
implicate procedural, patient and/or practitioner
variables.
Procedural factors
With respect to procedural factors, previous audits have
reported incomplete local implementation of monitoring
guidelines [11], poor communication of test results to
clinical teams, lack of communication between primary
and secondary care [12] and a lack of dedicated monitor-
ing services and central registers that generate reminders
that tests are due [10,13]. Our study corroborates these
Table 2 Results of prior, published UK audits of lithium monitoring
Study Number
of
patient
records
audited
Mean
age:
years
%
female
% with a
diagnosis of
bipolar
disorder
% meeting standard
relating to
monitoring lithium
level
% meeting standard
relating to
monitoring
renal function
% meeting
standard relating
to monitoring
thyroid function
Standards
used in
audit
Current study 2,976 55 59 57 30
68
55
81
50
82
NICE
QOF
Kehoe & Mander
1992 9 (Edinburgh)
458 56 68 56 < 81 - - BNF
*Eagles et al 2000 11
(Aberdeen)
422
403
-
54
-
63
-
-
54
54
71
78
44
55
BNF
Ryman 1997 34
(Gateshead)
290 56 - - 69 67 47 BNF
Fielding et al 1999 10
(Southampton)
246 79 72 18 84 84 84 BNF
Head 1998) 23
(Cambridge)
148 65-87 76 56 36 74 80 BNF
+Farooqi et al 2002 13
(Leicestershire)
92
122
-
-
-
-
-
-
43
57
42
62
59
61
BNF
Glover & Lawley
2005 8 (Hull)
?50 - - - 52 66 64 BNF
*Comparison of monitoring practice before and after the distribution of monitoring guidelines.
+Comparison of monitoring practice before and after the introduction of a local register.
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findings by revealing variable adoption of monitoring
guidelines and use of shared care protocols by mental
health Trusts, with few clinicians having electronic access
to test results. In addition, few Trusts operate designated
lithium clinics and only one reported having a local data-
base specifically for lithium that produced automatic
prompts when biochemical tests were due.
Communication could be improved through the devel-
opment of local registers of lithium-treated patients (with
systems for review and recall), and local needs assessment
(complemented by audit, training and the use of appropri-
ate guidelines) [12-14]. Bringing primary and secondary
care teams together to agree on a model of shared care
suited to local needs may also be important [14].
Patient factors
Previous studies have identified a number of patient-
related factors that may influence monitoring rates.
These include variation in the willingness of patients to
have blood tests [15,16], and either receiving inadequate
information about lithium treatment and the need for
regular blood tests or not assimilating the information
given [8,17,18]. Our findings provide support for the
view that many patients are not provided with basic
information about their lithium treatment.
Patient demographics may plausibly influence the qual-
ity of monitoring of psychotropic medication [19], but to
what extent this would be driven by variable engagement
with healthcare by patients and the behaviour of clini-
cians is uncertain. Our study did not identify any contri-
bution from gender or ethnicity, but found that
monitoring practice for patients cared for by older peo-
ples services was generally better than that provided by
general adult services. This may reflect that clinicians in
elderly services have an increased awareness of lithium
monitoring requirements for their patients, who are par-
ticularly vulnerable to renal side-effects, and in whom the
background prevalence of thyroid problems is higher
than in younger adults. Our audit also revealed slightly
superior monitoring of body weight for patients with a
diagnosis of a schizophrenia spectrum disorder, which
may indicate increased clinician awareness of risk factors
for weight gain in such patients [20,21].
Practitioner factors
With respect to practitioner-related factors, several stu-
dies report superior standards of lithium monitoring for
patients under the care of a psychiatrist [9,11,22] while
others report no difference from the quality of monitor-
ing undertaken by general practitioners [23,24]. Some
audits also report superior monitoring for those patients
in nurse-led, designated lithium clinics [10] or under
pharmacist supervision [25]. It has been suggested that
the large variation in the degree of knowledge about
Table 3 Effect of patient characteristics on monitoring quality (NICE standards)
n(%) of all patients: n (%) of patients in each demographic or clinical group meeting NICE
monitoring standards for:
Lithium levels Renal function (Cr) Thyroid function Body weight
Sex Male 1270 (42.7%) 363 (28.6%) 703 (55.4%) 600 (47.2) 371 (29.2%)
Female 1706 (57.3%) 539 (31.6%) 925 (54.2%) 876 (51.3%) 450 (26.4%)
Age <65 2068 (69.5%) 587 (28.4%) 1060 (51.3%) 1000 (48.4%) 599 (29.0%)
>65 908 (30.5%) 315 (34.7%) 568 (62.6%) 476 (52.4%) 222 (24.4%)
Ethnicity White British 2356 (79.2%) 709 (35.1%) 1264 (53.7%) 1162 (49.3%) 650 (27.6%)
Black British 79 (2.7%) 18 (22.8%) 45 (57.0%) 42 (53.2%) 31 (39.2%)
Asian 118 (4%) 32 (27.1%) 70 (59.3%) 58 (49.2%) 43 (36.4%)
Other 53 (1.8%) 13 (24.5%) 30 (56.6%) 30 (56.6%) 22 (41.5%)
Not stated 370 (12.4%) 130 (35.1%) 219 (59.2%) 184 (49.7%) 75 (20.3%)
ICD code F20-29 326 (11%) 97 (29.8%) 182 (55.8%) 151 (46.3%) 127 (39.0%)
F30-39 2451 (82.4%) 753 (30.7%) 1349 (55.0%) 1245 (50.8%) 623 (25.4%)
Other 137 (4.6%) 27 (19.7%) 59 (43.1%) 50 (36.5%) 62 (45.3%)
Not known 62 (2.1%) 25 (40.3%) 38 (61.3%) 30 (48.4%) 9 (14.5%)
Care provider General adult service 2155 (72.4%) 621 (28.8%) 1141 (52.9%) 1081 (50.2%) 549 (25.5%)
Older peoples service 568 (19.1%) 220 (38.7) 374 (65.8%) 309 (54.4%) 142 (25.0%)
Forensic service 76 (2.6%) 36 (47.4%) 60 (78.9%) 43 (56.6%) 56 (73.7%)
Learning disabilities 136 (4.6%) 22 (16.2%) 38 (27.9%) 34 (25.0%) 60 (44.1%)
Other service 41 (1.4%) 3 (7.7%) 14 (35.8%) 9 (23.1%) 12 (30.8%)
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lithium and its monitoring requirements amongst indivi-
dual professionals may account for these inconsistent
findings [26]. There may also be variation between clini-
cians in the acceptance of the need for monitoring at
the frequency recommended by NICE.
The use of incentivised care in improving monitoring
practice
Mental health Trusts within the UK are required to
implement NICE guidelines and progress with this is
monitored by the Care Quality Commission (CQC). In
contrast, there are no sanctions for General Practitioners
who fail to meet QOF targets, rather a positive benefit in
the form of payment when these targets are met.
In our sample, the primary care QOF targets with
respect to monitoring of serum lithium was met in over
two-thirds of cases, and the target with respect to renal
and thyroid function in just over four fifths. The NHS
Information Centre (QOF statistics for England, 2008/9)
lists these targets as having been met for 91% and 97.4% of
patients respectively within primary care in 2008/9 [27].
As it is likely that the care of the majority of patients who
are prescribed lithium is shared between primary and sec-
ondary care, less apparent monitoring in our secondary
care sample may partly reflect communication issues
between these sectors.
Proponents of a system like QOF argue that it can
improve the implementation of evidence-based interven-
tions [28] in primary care and constitutes an important
quality improvement tool. However, critics have
expressed concerns that QOF targets are too low with
poor discriminatory value [29], and that incentivised
care will never be an adequate substitute for profes-
sional judgment [30]. Our finding that the proportion of
patients monitored in line with QOF targets was higher
in primary than secondary care supports the view that
the QOF system is a viable quality improvement tool.
There is however, a need for more objective and trans-
parent setting of QOF targets and increasing conver-
gence between these and NICE standards.
Study strengths and limitations
A possible limitation of our study is a bias in the selec-
tion of patient samples for audit by each participating
Trust. Such bias is unlikely to be unidirectional in that
clinical teams that consider they are performing well in
relation to meeting the relevant practice standards may
choose to participate, whereas Trusts may choose to
submit data for teams that they suspect are performing
less well. The net result of competing sources of bias is
unknown. Poor documentation standards or quality of
case note review in this audit could also account for
observed failures in monitoring practice.
A strength of the work is that our audit sample is lar-
ger than those of all previously published studies com-
bined and is drawn from across the UK. Trusts that
participated in the audit are representative of all NHS
mental health Trusts [31] and so it is likely that our
findings are generalisable to practice in other Trusts and
representative of current clinical practice in the UK.
Conclusions
This is the first, published, national-level audit of
lithium prescribing and monitoring practice in the UK.
Our findings suggest that contemporary lithium moni-
toring falls short of the standards recommended by
NICE. Failure to provide adequate information to ensure
the safe use of lithium and/or to ensure adequate moni-
toring of established treatment, may place patients at
risk of avoidable drug related morbidity.
The National Patient Safety Agency (NPSA) is a special
health authority that was established in 2001. Its role is
to co-ordinate information about harm caused in health
care settings, and to work with partner organisations to
reduce such harm. Partly in response to the findings
from this audit and partly in response to reported patient
safety incidents related to lithium, the NPSA issued a
Patient Safety Alert with actions requiring that primary
care, mental health and acute Trusts, along with hospital
pathology services ensure systems are put in place to sup-
port the monitoring associated with lithium treatment
that is recommended by NICE [32]. The NPSA has also
endorsed a patient-held pack which contains information
about treatment including how to avoid toxicity, and a
biochemical monitoring record [33,34]. The deadline for
getting information to patients and having these moni-
toring systems in place is December 2010.
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